No Data
Express News | Huiyu Pharmaceutical: HYP-6589 tablets approved for clinical drug trials.
Huiyu Pharmaceutical (688553.SH): The injection of Tekrolin has obtained a pharmaceutical registration certificate
Gelonghui November 5th丨Huiyu Pharmaceutical (688553.SH) announced that it has recently received the "Pharmaceutical Registration Certificate" issued by the National Medical Products Administration. The pharmaceutical name is: Injection of Teklannin. Teklannin is a glycopeptide antibiotic that inhibits bacterial cell wall synthesis and kills bacteria. The site of action of Teklannin is different from that of β-lactam antibiotics, as it specifically binds to the residues of D-alanyl-D-alanine, blocking the peptidoglycan synthesis in bacterial cell walls.
Third Quarter Report 2024
Huayu Pharmaceutical (688553.SH): The net income in the first three quarters was 0.227 billion yuan, a year-on-year increase of 155.62%.
Glory 10月25日丨Huiyu Pharmaceuticals (688553.SH) announced its third quarter report for 2024, with a company's revenue of 0.852 billion yuan in the first three quarters, a year-on-year increase of 29.24%; net income attributable to shareholders of the listed company was 0.227 billion yuan, a year-on-year increase of 155.62%; net profit attributable to shareholders of the listed company after deducting non-recurring losses was 0.1 billion yuan, a year-on-year increase of 141.81%; basic earnings per share was 0.54 yuan.
Express News | Huiyu Pharmaceutical: Net income in the third quarter increased by 701.17% year-on-year.
Express News | Huiyu Pharmaceutical: Acetylglutathione injection obtained pharmaceutical registration certificate.
No Data
No Data